本帖最后由 老马 于 2012-1-13 21:20 编辑
& K: C- D" ]' Y% R( D, B
: ^. M0 Y4 ]9 U; O9 j爱必妥和阿瓦斯丁的比较; j y5 S4 A% P; c6 ^1 w
. q( S0 n0 T) [! |) Q7 l
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 G' e9 q3 |. A0 ~ l
* Q3 P* N, H! C. I
% A: H1 t8 j, V4 q, L/ mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ f8 b4 B, ]+ _; W* s
==================================================
6 A- b. l7 U. ? [Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% \0 e) [& Y7 x& R4 i1 _
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.: n* i! h" b, v3 s _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.# \9 O3 a0 p& I2 q8 C+ ?9 k/ |
|
11011102001537 )
显身卡
2 b2 C3 T; n2 [' t/ h4 R$ e8 C
